gliclazide has been researched along with liraglutide in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Jermendy, G | 1 |
| García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G | 1 |
| Bi, Y; Chen, W; Feng, W; Gao, C; Li, P; Shen, S; Wu, M; Yin, T; Zhu, D | 1 |
| Bien, Z; Heald, AH; Laing, I; Livingston, M; Moreno, GYC; Stedman, M | 1 |
| Bi, Y; Feng, WH; Gao, CX; Gao, LJ; Li, P; Shen, SM; Yang, DH; Yin, TT; Zhu, DL | 1 |
| Fu, BY; Wang, XJ | 1 |
1 review(s) available for gliclazide and liraglutide
| Article | Year |
|---|---|
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
2 trial(s) available for gliclazide and liraglutide
| Article | Year |
|---|---|
Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.
Topics: Adipose Tissue; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Liver Function Tests; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease | 2017 |
Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Liver Function Tests; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Prognosis; Prospective Studies; Young Adult | 2019 |
3 other study(ies) available for gliclazide and liraglutide
| Article | Year |
|---|---|
Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Lipids; Liraglutide; Liver Function Tests; Male; Metabolic Syndrome; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Peptides; Pilot Projects; Pioglitazone; Prospective Studies; Sitagliptin Phosphate; Thiazolidinediones; Venoms; Waist Circumference | 2016 |
The pattern of prescribing of glucose modulating agents for type 2 diabetes in general practices in England 2016/17.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Drug Prescriptions; England; Exenatide; General Practice; Gliclazide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Practice Patterns, Physicians'; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Venoms | 2018 |
The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases.
Topics: Diabetes Mellitus, Type 2; Exenatide; Gliclazide; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Sitagliptin Phosphate | 2022 |